Atac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atac

Property Description
Active Ingredient Naproxen Sodium
Form Oral tablet (Film-coated)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Symptomatic relief of musculoskeletal pain and inflammation
Origin Synthetic compound

What is Atac and What Pharmacological Class Does it Belong To?

Atac is a trade name for a medication whose active ingredient is Naproxen Sodium, a synthetic compound classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Within this classification, Naproxen is recognized as an analgesic and anti-inflammatory agent. Atac is designed as a single-ingredient product intended for systemic action to relieve discomfort throughout the body. The overall efficacy of Naproxen Sodium in managing systemic inflammation is clinically recognized.

Composition and Drug Form: Naproxen Sodium Tablets

The core composition of Atac relies on the active ingredient Naproxen Sodium, which is formulated for oral administration primarily as an oral tablet or a film-coated tablet. A distinguishing feature of this composition is the presence of the sodium salt, which facilitates rapid absorption of the Naproxen component compared to the non-salt form, allowing the active substance to reach its target physiological sites more efficiently. This expedited absorption is a key differentiating factor that influences its application for acute pain. The final drug form is manufactured with specific solid pharmaceutical excipients to maintain its stability and ensure a predictable release profile following oral ingestion.

General Purpose: Relief of Pain, Inflammation, and Fever

The general purpose of Atac stems directly from its classification, aiming to provide effective symptomatic relief by managing three cardinal symptoms: pain (analgesia), inflammation, and fever (antipyresis). For example, it is typically used to address the discomfort and swelling associated with minor injuries or muscle strains. By addressing both discomfort and the underlying inflammatory response, this NSAID offers a broad utility for individuals requiring general reduction of pain and elevated body temperature.

Regulatory References

  1. NSAID
  2. WHO Essential Medicines
  3. NIH MedlinePlus

What side effects are possible with Atac?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety-related information for this medicine, based strictly on government regulatory documents.

Adverse Reactions by Frequency

Side effects are categorized by how often they occurred in clinical trials, providing a statistical overview of the expected safety profile:

  • Very Common (Affects 10% or more): Hot flushes, headache, asthenia (weakness), arthralgia (joint pain) or joint stiffness, and arthritis.
  • Common (Affects 1% to 10%): Nausea, vomiting, diarrhea, rash, alopecia (hair loss), depression, hypertension (high blood pressure), carpal tunnel syndrome, pharyngitis, insomnia, peripheral edema, osteoporosis, fractures, and hypercholesterolemia (high cholesterol levels).
  • Uncommon (Affects 0.1% to 1%): Hepatitis (inflammation of the liver), hypercalcaemia (high calcium levels), and urticaria (hives).
  • Rare (Affects 0.01% to 0.1%): Severe skin reactions, including erythema multiforme, and specific allergic reactions like anaphylactoid reaction or cutaneous vasculitis.
  • Very Rare (Affects less than 0.01%): Severe skin reactions, including Stevens-Johnson syndrome, and angioedema (swelling of the face, tongue, or throat).

Clinically Significant Safety Information

Safety concerns are also organized by the body system affected (System-Organ Class):

System-Organ Class Key Safety Consideration
Musculoskeletal Long-term use is associated with a reduction in bone mineral density and an increased risk of fractures.
Cardiovascular An increase in total cholesterol levels is common. In a major clinical trial, a higher incidence of ischemic cardiovascular events was observed in women with pre-existing ischemic heart disease.
Hepatobiliary Rare instances of hepatitis and changes in liver function blood tests have been documented.

Safety Restrictions and Limitations

The medicine is contraindicated and must not be used in specific situations, including patients with a known hypersensitivity to the drug or any of its components, and women who are or may become pregnant due to the potential for fetal harm. Caution is advised for patients with moderate to severe hepatic impairment. Furthermore, the medicine is not indicated for premenopausal women.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Naproxen Sodium (Atac) is defined by officially documented symptoms and the potential for severe systemic outcomes, requiring specific emergency action as mandated by regulatory authorities. The profile highlights that there is no specific antidote known.

Documented Manifestations and Severe Outcomes

Overdose may initially present with common signs that are generally reversible with supportive care, including nausea, vomiting, epigastric pain, lethargy, drowsiness, and tinnitus.

Official labeling also recognizes the potential for severe and life-threatening complications, which include gastrointestinal bleeding, acute renal failure, hypertension, and neurological events such as convulsions and coma.

Immediate Actions and Supportive Management

Immediate medical attention must be sought for any suspected large overdosage or if severe symptoms are observed. Patients experiencing signs such as bloody stools, chest pain, or difficulty breathing require urgent medical evaluation.

Management is strictly symptomatic and supportive. While procedures like hemodialysis are generally not considered useful, the administration of activated charcoal may be considered for symptomatic patients seen within four hours of ingesting a large overdosage. Hospital monitoring for signs of cardiac ischemia may be required, particularly for individuals with a recent history of myocardial infarction.

Therapeutic Uses of Atac

Atac (Naproxen Sodium) is applied in contexts where a combination of symptoms related to physical discomfort, pain, and fever creates noticeable interference with daily stability. The overall therapeutic goal is to provide supportive relief that helps ease the overall symptom burden across acute and chronic manifestations. The medication is considered relevant across therapeutic domains involving inflammatory or irritative states, such as in conditions like osteoarthritis, rheumatoid arthritis, and acute gouty arthritis, and may also be applied when short-term symptomatic assistance is needed for fever and pain management.


The medication is considered relevant in contexts involving inflammatory or irritative processes associated with tenderness, swelling, and stiffness. It may be part of symptomatic management to address symptoms linked to inflammatory states in chronic conditions. It is commonly used to help with symptoms related to systemic imbalance, which may include fever and generalized body aches, and the acute, cramping symptoms of primary dysmenorrhea (menstrual cramps).

“The primary goal is to provide supportive relief that helps ease the overall symptom burden across acute and chronic manifestations.”

In clinical settings that involve acute or unstable symptom patterns, such as injuries like sprains and strains or episodes like migraine headaches, Atac may assist with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Supports Management of Joint Stiffness


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Atac (Naproxen Sodium) is subject to population eligibility rules defined by government regulatory agencies. The medicine is primarily intended for use by Adults and Adolescents (typically 12 years and older for non-prescription use). Safety and efficacy are not established for children under specific age thresholds, such as those under 2 years for most indications.

The medicine is contraindicated and must not be used in certain populations, including individuals with a known hypersensitivity to naproxen or other NSAIDs (like aspirin), those with active gastrointestinal bleeding, ulceration, or severe heart failure. It is also strictly contraindicated in women starting at 30 weeks’ gestation or later ( third trimester of pregnancy) and in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Restricted use applies to populations with specific pre-existing conditions. These include older adults ( 65 years and older) and patients with a history of GI ulcers, hypertension, or mild to moderate renal/hepatic impairment. Use in these groups is generally conditional, often requiring the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific drugs and product classes that should not be used concurrently due to the potential for a reduction in the pharmacological action of Atac (Anastrozole). These interactions are classified as clinically significant and necessitate a restriction on co-administration.

Category Interacting Products or Classes Regulatory Stance / Constraint
Hormonal Therapies Estrogen-containing products Co-administration should be avoided as these agents counteract the drug's intended activity.
Selective Estrogen Receptor Modulators (SERMs) Tamoxifen Co-administration should be avoided as it is documented to reduce the plasma concentration of Anastrozole.
Food and Supplements Food/Meals Food does not affect the overall extent of drug absorption; no meal-timing requirements are imposed for the drug's efficacy.

Co-administration with Tamoxifen or any estrogen-containing therapy is officially restricted because these combinations diminish the drug's established effects. These include hormone replacement therapies and other forms of exogenous estrogen. The primary concern is the potential for pharmacodynamic conflict, which could reduce the therapeutic effect. Population-specific notes indicate that Anastrozole exposure is not significantly increased in subjects with severe renal impairment, but caution is still recommended for patients with moderate and severe hepatic impairment.

Mechanism of Action

The action of Naproxen Sodium is governed by two primary, interrelated mechanistic domains that result in the modulation of defined lipid signaling pathways. The sodium salt formulation further influences the speed at which these mechanisms engage.

Inhibition of Cyclooxygenase Enzymes

The drug acts by reversibly inhibiting the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular blockade specifically targets the Arachidonic Acid Cascade, thereby preventing the biosynthesis of various signaling molecules known as prostaglandins. This suppression of mediator production is the core mechanistic step that defines the resulting pathway output.

Central and Peripheral Pathway Modulation

The mechanism exerts influence over two distinct functional systems. Peripherally, limiting prostaglandin synthesis reduces the chemical messaging that normally sensitizes nerve endings and drives vascular changes, such as fluid accumulation. Centrally, the mechanism alters the activity of thermoregulatory pathways within the hypothalamus, by blocking the specific prostaglandin responsible for elevating the body's temperature set-point. These actions collectively modify central and peripheral signaling dynamics.

Dosage and Administration Information

The administration of Atac (Naproxen Sodium) follows specific parameters established for the medication. The approved route of administration for all systemic tablet and suspension forms is oral.

Standard practice involves using the lowest effective dose for the shortest duration necessary to control symptoms. Dosing regimens vary depending on the usage context. For chronic conditions like arthritis, the typical maintenance dose falls within the range of 500 mg to 1000 mg of naproxen per day, usually administered in two divided doses. Conversely, acute situations such as a gout flare require an initial higher loading dose (e.g., 825 mg naproxen sodium) followed by subsequent smaller doses every 8 hours until the attack subsides.

To ensure proper administration, tablets may be taken with food, milk, or an antacid to minimize potential gastrointestinal discomfort. Certain formulations, specifically delayed-release or controlled-release tablets, must be swallowed whole and must not be crushed, broken, or chewed to maintain their functional integrity and drug release profile. Specific dosage adjustments are utilized for certain populations; for instance, older adults typically start at the lowest effective dose, and use is not recommended for individuals with severe renal impairment.

Recent Clinical Evidence

Evidence for Symptomatic Relief in Chronic Conditions

This section summarizes the structure of clinical research, including Randomized Controlled Trials (RCTs) and systematic reviews, that have examined the use of Atac for exploring symptomatic patterns in chronic inflammatory joint conditions.

Research Structure for Osteoarthritis

Research for this condition was evaluated in short-term and intermediate-term controlled studies. These studies were used in research exploring how symptoms change over time in patients with knee or hip involvement. Researchers monitored patient-reported outcomes describing perceived discomfort, including validated pain scales, and conducted assessments of joint stiffness and overall functional activity level. The evidence contributes to understanding symptom patterns but is not intended to predict whether an individual will respond similarly.

Research Structure for Rheumatoid Arthritis

For rheumatoid arthritis, the evidence was observed in controlled trials and systematic reviews, primarily focusing on outcomes linked to inflammatory or irritative states. The data show patterns related to symptomatic recording, particularly when Atac was studied for use alongside other common long-term treatments. Existing studies provide limited information for long-term outcomes regarding the progression of the underlying disease; the research primarily focuses on outcomes related to systemic or functional imbalance.


Evidence for Acute Pain and Inflammation Management

This section summarizes the evidence base relevant in trials assessing short-term or episodic symptom patterns for Atac in acute situations, detailing the study designs and the specific symptom metrics that was observed and recorded.

Acute Study Design for Musculoskeletal Injuries (Sprains and Strains)

The research for acute musculoskeletal pain was evaluated in short-term RCTs, where the follow-up durations were limited to a few days or weeks. These studies research examined outcomes describing episodic or acute changes in pain intensity, the assessment of inflammation, and measures of functional stability. Findings describe patterns observed in the studies relating to short-term changes in these symptoms.


What Research Gaps and Uncertainties Exist for Atac

The research, while comprehensive in certain acute conditions, has several limitations. Long-term effects are not fully established for symptomatic changes over many years, as follow-up durations were limited in many pivotal trials. Comparative evidence against some other treatments is limited or variable, meaning subgroup findings are uncertain for certain pain categories. Furthermore, the evidence applies only to the populations studied, and data for certain groups remain insufficient (e.g., complex patient cohorts with multiple health conditions). Research describes changes monitored during the study period but is not intended to predict whether an individual will experience similar patient-reported outcomes describing perceived discomfort.

Key Studies & References

  1. Naproxen (Oral) - NIH MedlinePlus Drug Information
  2. National Institutes of Health (NIH) - PubMed Central (Clinical Trials and Studies)

Frequently Asked Questions (FAQ)

Common questions about Atac (FAQ)

Q: Is Atac used for conditions other than the main ones listed?

A: Official regulatory documents define the uses of the active ingredient, Naproxen Sodium, for treating specific conditions, including various chronic inflammatory joint conditions, certain acute painful conditions like gout, and primary dysmenorrhea. Information provided to patients is strictly limited to these officially approved indications. Any use outside of the officially approved indications is not supported by regulatory-sourced patient information.


Q: Is Atac the same type of medicine as [similar common drug]? What is the difference?

A: Atac is a trade name for Naproxen Sodium, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Regulatory information notes that the sodium salt formulation allows for more rapid absorption into the body compared to the non-salt form, which can influence its application for acute symptoms.


Q: Can I take Atac if I am already on supplements like vitamins or herbs?

A: Information in patient materials indicates that use of any supplements, vitamins, or herbal remedies should be discussed with a healthcare provider. This is because formal studies on interactions with these types of products are often not conducted in the same way as for prescription medicines.


Q: Does Atac interact with common over-the-counter pain relievers?

A: Official guidance indicates that co-administration of Atac with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including other over-the-counter naproxen, aspirin, or ibuprofen products, is generally restricted. Combining NSAIDs significantly increases the documented risk of serious gastrointestinal side effects, such as bleeding and ulceration.


Q: Can Atac be taken with antacids?

A: Yes. Official documents confirm that Atac may be taken with food, milk, or antacids. Regulatory information indicates this is done to minimize the potential for stomach upset or gastrointestinal discomfort, which are common effects of this class of medicine.


Q: Is the side effect profile different for different dosages of Atac?

A: Regulatory guidance emphasizes that using the lowest effective dose for the shortest duration possible is a measure intended to minimize the potential for adverse events. This principle aligns with the documented safety profile, where the risk of side effects may be dose-dependent.


Q: How quickly should I notice the effects of Atac?

A: The active component, Naproxen, is designed to be rapidly and completely absorbed after ingestion. Specific naproxen sodium formulations are described in official documents as allowing for a prompt onset of pain relief for acute painful conditions, due to rapid absorption.


Q: How long does a dose of Atac stay in my system?

A: The elimination half-life of Naproxen, the active component, typically ranges from 12 to 17 hours. This figure represents the time required to clear half of the drug from the system.


Q: Can Atac cause long-term problems or side effects?

A: Official safety warnings indicate that long-term use of the active ingredient is associated with certain documented risks. These include an increased risk of serious gastrointestinal adverse events (bleeding) and serious cardiovascular thrombotic events (heart attack or stroke), as well as a reduction in bone mineral density.


Q: Is it common to feel [vague side effect, e.g., tired] when starting Atac?

A: Official regulatory documents list asthenia (weakness or lack of energy) as a very common side effect, affecting 10% or more of patients in clinical trials. Drowsiness is also frequently listed as a common side effect in patient information.


Q: Is it safe to drive or operate machinery while taking Atac?

A: Official labeling includes warnings that the active ingredient can cause drowsiness, dizziness, or vision disturbances. Official labeling states that caution should be exercised when driving or operating machinery, as it is unknown how the medicine will affect an individual user.


Q: Is Atac suitable for people who are elderly?

A: Yes, but with caution. Elderly patients are considered to be at a greater risk for developing serious gastrointestinal adverse events. For this reason, official guidance states that older adults must start treatment at the lowest effective dose for the shortest duration possible.


Q: Is Atac used in children?

A: Official eligibility rules state the medicine is primarily intended for use by Adults and Adolescents (typically 12 years and older for non-prescription use). Safety and efficacy are not established for children below certain age thresholds (e.g., 2 years) for most indications.


Q: Can Atac affect my mood or mental health?

A: Official safety documents list depression and insomnia (difficulty sleeping) as common side effects, affecting between 1% and 10% of patients in clinical trials. This indicates a potential for effects on mood and mental state according to regulatory sources.


Q: Are there any specific foods or drinks I need to avoid while on Atac?

A: Regulatory documents explicitly advise patients to avoid alcohol while taking the medicine. Combining alcohol with this Non-Steroidal Anti-Inflammatory Drug (NSAID) significantly increases the documented risk of stomach bleeding.


Q: Is there a maximum time someone can safely take Atac?

A: Official guidance emphasizes using the medicine for the shortest duration necessary for symptom relief. Over-the-counter (OTC) use is often limited to a maximum of 10 days for pain or 3 days for fever, unless a prescriber determines ongoing use is necessary for a chronic condition.


Q: What is the risk of having a serious allergic reaction to Atac?

A: The medicine carries an official warning for severe allergic reactions, especially in people allergic to aspirin or other NSAIDs. Rare documented occurrences include serious events like anaphylaxis (severe allergic shock), angioedema, and Stevens-Johnson syndrome (a severe skin reaction).


Q: Are there different forms of Atac (e.g., tablet, liquid, extended-release)?

A: Yes, the active ingredient, Naproxen Sodium, is available in multiple dosage forms according to official labeling. These generally include immediate-release tablets, delayed-release tablets (enteric-coated), and oral suspension (liquid) forms.


Q: Why does Atac need to be taken with food, if that's the instruction?

A: Official patient information indicates that taking the medicine with food, milk, or antacids is a way to minimize the potential for stomach upset or irritation. This is a common issue with this class of medicine.


Q: Can Atac cause weight gain or loss?

A: Official safety documents list peripheral edema (swelling) as a common adverse reaction, affecting 1% to 10% of patients in clinical trials. The official documentation lists fluid retention and edema (swelling) as observed adverse reactions.


Q: What should I do if a minor side effect of Atac doesn't go away?

A: Official patient information indicates that the medicine should be discontinued and a prescriber consulted if a condition worsens, if new symptoms appear, or if pain lasts longer than 10 days or fever lasts longer than 3 days.


Q: What makes Atac work differently from older medicines for the same condition?

A: The active ingredient, Naproxen, is an NSAID. The official documents describe the sodium salt formulation as being absorbed more rapidly, which is a key difference in how quickly the drug may begin working compared to the non-salt form.


Q: Can Atac cause dizziness?

A: Yes, official safety documents and patient information list dizziness as an adverse reaction that is considered common or frequent in patients taking the medicine.


Q: Does Atac interact with alcohol?

A: Yes, official regulatory documents explicitly warn that combining this medicine with alcohol significantly increases the risk of gastrointestinal irritation and stomach bleeding.


Q: Is Atac safe to take while breastfeeding?

A: The active ingredient, Naproxen, has been found in the milk of lactating women at low concentrations. Specialized government resources indicate that levels are low and adverse effects in breastfed infants are uncommon. Specialized government resources note that caution should be exercised, particularly when nursing a newborn.


Q: Does taking Atac affect fertility?

A: Regulatory documents state that use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may potentially impair female fertility. Official information also notes that this effect is often reversible upon stopping the medicine.


Q: Can Atac interact with herbal teas or natural remedies?

A: Information in patient materials indicates that use of any supplements, including herbal teas and natural remedies, should be discussed with a healthcare provider. Formal interaction data is often limited.


Q: What is the typical timeframe for a treatment course with Atac?

A: Treatment length varies based on the condition being addressed. For short-term pain relief, the typical course (over-the-counter use) is usually no more than 10 days. Use for chronic conditions requires ongoing treatment as determined by a prescriber.


Q: Are there any specific symptoms that signal I need urgent medical attention while on Atac?

A: Yes, official safety information lists specific signs that require immediate medical attention. These include symptoms such as chest pain, trouble breathing, sudden weakness, slurred speech, black or bloody stools, and vomiting blood.


Q: Can Atac be split or crushed if I have trouble swallowing pills?

A: Specific tablet formulations, such as delayed-release or controlled-release tablets, must be swallowed whole and must not be crushed, broken, or chewed. Breaking these can interfere with how the medicine is absorbed, according to official documents.


Q: Is it possible to get a generic version of Atac?

A: Atac is a brand name for the active ingredient Naproxen Sodium. Generic versions of Naproxen Sodium tablets are widely available once the patent and exclusivity periods have expired for the original brand product, as indicated in official drug databases.

How should Atac be stored and disposed of?

The official labeling for Atac (Naproxen Sodium) mandates specific storage and handling to ensure its stability up to the expiration date.

Storage & Disposal Scope Official Regulatory Requirement
Labeled storage temperature requirements Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F), with excursions permitted up to 30 C (86 F).
Light/moisture protection requirements Protect from light and avoid high humidity and excessive heat above 40 C (104 F).
Packaging-related storage rules Keep in the tightly closed, original container and dispense in a well-closed, light-resistant container.
Child-protection storage requirements Must be stored out of the sight and reach of children.
Disposal instructions Dispose of any unused product or waste material in accordance with local requirements.

Storage conditions are set to maintain product integrity and strength. Disposal must be performed according to mandated local regulations, preventing environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atac found in:

A-Z Index: